117 related articles for article (PubMed ID: 35415908)
1. Novel pyrazolo[3,4-b]pyridine derivatives: Synthesis, structure-activity relationship studies, and regulation of the AMPK/70S6K pathway.
Guo Y; Jiang X; Chang Q; Xiao Z; Chen Z; Jiang D; Hu G; Li Q
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100465. PubMed ID: 35415908
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of pyrazolo-[3,4-b]pyridine derivatives as adenosine 5'-monophosphate-activated protein kinase activators.
Zheng B; Peng Y; Wu W; Ma J; Zhang Y; Guo Y; Sun S; Chen Z; Li Q; Hu G
Arch Pharm (Weinheim); 2019 Aug; 352(8):e1900066. PubMed ID: 31373047
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
4. One-pot three-component synthesis of novel pyrazolo[3,4-b]pyridines as potent antileukemic agents.
Barghash RF; Eldehna WM; Kovalová M; Vojáčková V; Kryštof V; Abdel-Aziz HA
Eur J Med Chem; 2022 Jan; 227():113952. PubMed ID: 34731763
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, cytotoxicity, antimicrobial and anti-biofilm activities of novel pyrazolo[3,4-b]pyridine and pyrimidine functionalized 1,2,3-triazole derivatives.
Nagender P; Malla Reddy G; Naresh Kumar R; Poornachandra Y; Ganesh Kumar C; Narsaiah B
Bioorg Med Chem Lett; 2014 Jul; 24(13):2905-8. PubMed ID: 24835633
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro antiproliferative activity of certain novel pyrazolo[3,4-b]pyridines with potential p38α MAPK-inhibitory activity.
Farahat AA; Samir EM; Zaki MY; Serya RAT; Abdel-Aziz HA
Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100302. PubMed ID: 34796536
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents.
Wang R; Chen Y; Yang B; Yu S; Zhao X; Zhang C; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Jan; 94():103474. PubMed ID: 31859010
[TBL] [Abstract][Full Text] [Related]
8. Zedoarondiol Inhibits Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cells Proliferation via Regulating AMP-Activated Protein Kinase Signaling Pathway.
Mao H; Tao T; Song D; Liu M; Wang X; Liu X; Shi D
Cell Physiol Biochem; 2016; 40(6):1506-1520. PubMed ID: 27997894
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
10. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
[TBL] [Abstract][Full Text] [Related]
11. Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.
Abreu RM; Ferreira IC; Calhelha RC; Lima RT; Vasconcelos MH; Adega F; Chaves R; Queiroz MJ
Eur J Med Chem; 2011 Dec; 46(12):5800-6. PubMed ID: 22014996
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
[TBL] [Abstract][Full Text] [Related]
13. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
14. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
15. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
16. 3,5-Diaryl-1H-pyrazolo[3,4-b]pyridines as potent tubulin polymerization inhibitors: Rational design, synthesis and biological evaluation.
Zhai M; Liu S; Gao M; Wang L; Sun J; Du J; Guan Q; Bao K; Zuo D; Wu Y; Zhang W
Eur J Med Chem; 2019 Apr; 168():426-435. PubMed ID: 30831410
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
18. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
19. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
